retatrutide triple agonist gip glp-1 glucagon receptor π¨ HOT OFF THE PRESS: Phase 3 data has arrived β and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average Retatrutide is a triple-agonist drug
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 13 - Aug 18

















00187-5/asset/eb17eccf-07a4-45a3-a12d-9267d643bc9d/main.assets/gr2_lrg.jpg)



.png)






